On February 26, 2018 Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, is hosting an analyst and investor event to present Phase 2 results from its HS-110 (viagenpumatucel-L) study in combination with the Bristol-Myers Squibb checkpoint inhibitor, nivolumab (Opdivo), in patients with advanced non-small cell lung cancer (NSCLC) whose cancers have progressed after treatment with one or more lines of therapy (Press release, Heat Biologics, FEB 26, 2018, View Source [SID1234524164]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will take place at 8 a.m., Wednesday, Feb. 28, 2018, at the Lotte New York Palace Hotel in New York City. To register and watch a live webcast of the event, visit View Source
The event follows the first formalized Independent Data Monitoring Committee ("IDMC") meeting review of the most recent Phase 2 interim data from the trial. The presentation will include data generated from the first 35 patients enrolled in the study, specifically:
Clinical efficacy measures of treatment response
The correlation of immune response from blood samples with positive clinical outcome
Safety data evaluation and analysis
Speakers include Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania and Associate Director for Clinical Research for the Abramson Cancer Center, who will discuss the current treatment landscape for NSCLC, and the emerging role of combination immunotherapy treatments. Following Dr. Cohen’s presentation, George Peoples, MD, Chief Medical Officer for Heat, will discuss the latest Phase 2 results from the HS-110 study. Heat management will also provide an outline of the company’s planned development strategy for HS-110 based on the trial data, as well as the recent outcome of its Type C meeting with the FDA.